Found: 6
Select item for more details and to access through your institution.
P-090: BRAF V600E multiple myeloma patient salvaged with triple MAPK inhibition after CAR T relapse.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S88, doi. 10.1016/S2152-2650(21)02224-2
- By:
- Publication type:
- Article
P-102: Genomic and systemic metabolism differences associated with racial disparities in Multiple Myeloma.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S94, doi. 10.1016/S2152-2650(21)02236-9
- By:
- Publication type:
- Article
P-063: Pathogenic germline variants in hereditary cancer genes in patients with Multiple Myeloma.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S73, doi. 10.1016/S2152-2650(21)02197-2
- By:
- Publication type:
- Article
OAB-053: Clinical outcomes of relapsed/refractory multiple myeloma patients after BCMA-targeted CAR T therapy.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S38, doi. 10.1016/S2152-2650(21)02133-9
- By:
- Publication type:
- Article
Correction: Triple MAPK inhibition salvaged a relapsed post-BCMA CAR-T cell therapy multiple myeloma patient with a BRAF V600E subclonal mutation.
- Published in:
- 2023
- By:
- Publication type:
- Correction Notice
Triple MAPK inhibition salvaged a relapsed post-BCMA CAR-T cell therapy multiple myeloma patient with a BRAF V600E subclonal mutation.
- Published in:
- Journal of Hematology & Oncology, 2022, v. 15, n. 1, p. 1, doi. 10.1186/s13045-022-01330-3
- By:
- Publication type:
- Article